Zoetis Inc. $ZTS Shares Sold by NewEdge Advisors LLC

Key Points

• NewEdge Advisors LLC has decreased its position in Zoetis Inc. by 6.6%, reducing its holdings to 34,648 shares valued at approximately $5.7 million after selling 2,463 shares in the first quarter.
• Zoetis reported a strong quarterly earnings result with an EPS of $1.76, beating estimates and achieving revenue of $2.46 billion, a 4.2% increase compared to the same quarter last year.
• Analysts have recently adjusted their ratings on Zoetis, with four analysts rating the stock as a Buy and four as a Hold, while the average price target is set at $202.43.

NewEdge Advisors LLC trimmed its position in Zoetis Inc. (NYSE:ZTS - Free Report) by 6.6% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 34,648 shares of the company's stock after selling 2,463 shares during the quarter. NewEdge Advisors LLC's holdings in Zoetis were worth $5,705,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also made changes to their positions in the company. Portside Wealth Group LLC increased its holdings in shares of Zoetis by 24.7% in the 1st quarter. Portside Wealth Group LLC now owns 33,709 shares of the company's stock valued at $5,550,000 after acquiring an additional 6,672 shares during the last quarter. Tandem Investment Advisors Inc. increased its holdings in shares of Zoetis by 100.3% in the 1st quarter. Tandem Investment Advisors Inc. now owns 395,626 shares of the company's stock valued at $65,140,000 after acquiring an additional 198,089 shares during the last quarter. Flagship Harbor Advisors LLC increased its holdings in shares of Zoetis by 31.2% in the 1st quarter. Flagship Harbor Advisors LLC now owns 7,394 shares of the company's stock valued at $1,217,000 after acquiring an additional 1,760 shares during the last quarter. Horizon Financial Services LLC bought a new stake in shares of Zoetis in the 1st quarter valued at approximately $380,000. Finally, Sage Rhino Capital LLC increased its holdings in shares of Zoetis by 117.6% in the 1st quarter. Sage Rhino Capital LLC now owns 7,014 shares of the company's stock valued at $1,155,000 after acquiring an additional 3,791 shares during the last quarter. 92.80% of the stock is currently owned by institutional investors.

Zoetis Stock Performance

ZTS stock traded down $2.28 during trading on Friday, reaching $148.33. 3,111,229 shares of the company's stock were exchanged, compared to its average volume of 2,249,190. The company has a quick ratio of 1.04, a current ratio of 1.76 and a debt-to-equity ratio of 1.05. Zoetis Inc. has a 1-year low of $139.70 and a 1-year high of $200.33. The company's fifty day moving average price is $152.32 and its 200-day moving average price is $157.21. The firm has a market cap of $65.74 billion, a PE ratio of 25.53, a P/E/G ratio of 2.38 and a beta of 0.88.

Zoetis (NYSE:ZTS - Get Free Report) last announced its quarterly earnings results on Tuesday, August 5th. The company reported $1.76 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.62 by $0.14. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.The company had revenue of $2.46 billion during the quarter, compared to analyst estimates of $2.41 billion. During the same quarter in the previous year, the firm posted $1.56 EPS. The firm's quarterly revenue was up 4.2% on a year-over-year basis. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. On average, research analysts expect that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on the company. Leerink Partners downgraded Zoetis from an "outperform" rating to a "market perform" rating and lowered their price target for the company from $180.00 to $155.00 in a report on Thursday, July 17th. Stifel Nicolaus downgraded Zoetis from a "buy" rating to a "hold" rating and lowered their price objective for the stock from $165.00 to $160.00 in a research note on Wednesday, June 18th. Argus restated a "buy" rating and set a $190.00 price objective on shares of Zoetis in a research note on Tuesday, September 9th. Leerink Partnrs downgraded Zoetis from a "strong-buy" rating to a "hold" rating in a research note on Thursday, July 17th. Finally, Piper Sandler upped their price objective on Zoetis from $210.00 to $215.00 and gave the stock an "overweight" rating in a research note on Monday, August 11th. Five analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat, Zoetis presently has a consensus rating of "Moderate Buy" and an average target price of $200.88.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.